MSST0031

SILu^™Prot MAPT Microtubule-associated protein tau-441 human

recombinant, expressed in HEK 293 cells, SIL MS Protein Standard, ¹³C and ¹⁵N-labeled

• Synonym(e): Isotopically labeled MAPT LC/MS standard, Isotopically labeled human Microtubule-associated protein tau-441, Neurofibrillary tangle protein human, Paired helical filament-tau (PHF-tau), Pairedhelicalfilament-tau(PHF-tau), Tau-F
• NACRES: NA.12
• UNSPSC Code: 23201100
• eCl@ss: 32150313
• Form: lyophilized powder
• Assay: ≥98% (SDS-PAGE)
• Biological source: human
• Recombinant: expressed in HEK 293 cells

Eigenschaften

• biological source: human
• Quality Segment: 200
• recombinant: expressed in HEK 293 cells
• assay: ≥98% (SDS-PAGE)
• form: lyophilized powder
• potency: ≥98 Heavy amino acids incorporation efficiency by MS
• technique(s): mass spectrometry (MS): suitable, protein mass spectrometry: suitable
• suitability: suitable for mass spectrometry (standard)
• UniProt accession no.: P10636
• storage temp.: −20°C
• Gene Information: human ... MAPT(4137)

Beschreibung

General description

Tau-441 is a member of the Tau family of proteins. Tau proteins are mainly expressed in the neurons of the central nervous system where they exert a role in stabilizing microtubules, key components of axonal transport, as well as in signal transduction.Tau proteins are subject to phosphorylation and this phenomenon regulates the association of the Tau protein with the microtubules. Deposits of Alzheimer′s disease AD-associated proteins, such as hyperphosphorylated Tau, as well as other shared misfolded proteins, such as, β-amyloid precursor protein (βAPP), ubiquitin, and various chaperones and protein kinases are thought to play a pathologic role in the cognitive decline and muscular failure.3 Malfunctioning of Tau proteins is associated with microtubules disintegration and collapsing of the neuronal transport system. Among other diseases, Tau forms in cerebrospinal fluid are considered a reliable biomarker for progressive supranuclear palsy, where the levels of Tau forms ratio were significantly reduced.

Immunogen

MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGLDRIRGRKLGPFEGKPIPNPLLGLDSTRTGHHHHHHHHGGQ

Biochem/physiol Actions

SILu^™Prot MAPT is a recombinant, stable isotope-labeled human MAPT which incorporates [¹³C₆, ¹⁵N₄]-Arginine and [¹³C₆, ¹⁵N₂]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of MAPT in mass-spectrometry. SILu Prot MAPT is a protein of 481 amino acids (including C-terminal V5 and polyhistidine tags) with a calculated molecular mass of 36 kDa.

Physical form

Supplied as a lyophilized powder containing phosphate buffered saline.

Legal Information

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.

SILu is a trademark of Sigma-Aldrich Co. LLC

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• WGK: WGK 2
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable